Description: Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in developing a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. It is involved in developing HPN424 that is in Phase I clinical trial for the treatment of metastatic castration-resistant prostate cancer; and HPN536 for the treatment of ovarian cancer and other mesothelin expressing tumors, as well as other products targeting tumor-associated antigens for the treatment of multiple myeloma and small-cell lung cancer. The company has a collaboration agreement with AbbVie Biotechnology Ltd. Harpoon Therapeutics, Inc. was founded in 2015 and is headquartered in South San Francisco, California.
Home Page: www.harpoontx.com
HARP Technical Analysis
131 Oyster Point Boulevard
South San Francisco,
CA
94080
United States
Phone:
650 443 7400
Officers
| Name | Title |
|---|---|
| Ms. Julie M. Eastland M.B.A. | Pres, CEO & Director |
| Dr. Natalie R. Sacks M.D. | Consultant |
| Ms. Georgia L. Erbez | Consultant |
| Dr. Holger Wesche Ph.D. | Chief Scientific Officer |
| Ms. Wendy Chang | Sr. VP of HR |
| Ms. Rachael Lester | Sr. VP of Bus. Devel. & Corp. Strategy |
| Dr. Banmeet Anand Ph.D. | Sr. VP of Translational Medicine |
| Dr. Luke N. Walker M.D. | Chief Medical Officer |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.4933 |
| Price-to-Sales TTM: | 0.7455 |
| IPO Date: | 2019-02-08 |
| Fiscal Year End: | December |
| Full Time Employees: | 86 |